Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

13 trials with published results (15%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

7.1%

6 terminated out of 84 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

4%

3 trials in Phase 3/4

Results Transparency

27%

13 of 48 completed with results

Key Signals

13 with results89% success

Data Visualizations

Phase Distribution

73Total
Not Applicable (6)
Early P 1 (1)
P 1 (30)
P 2 (33)
P 3 (3)

Trial Status

Completed48
Unknown14
Recruiting7
Terminated6
Withdrawn4
Active Not Recruiting3

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 48 completed trials

Clinical Trials (84)

Showing 20 of 20 trials
NCT07550049Not Yet Recruiting

Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology

NCT03710876Phase 3CompletedPrimary

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

NCT05655078Not ApplicableRecruitingPrimary

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

NCT04897022Phase 1Active Not RecruitingPrimary

A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma

NCT00797719Phase 1CompletedPrimary

Short Neoadjuvant Hemithoracic IMRT for MPM

NCT02662504Phase 2CompletedPrimary

Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma

NCT04334759Phase 3Completed

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

NCT03269227Not ApplicableActive Not RecruitingPrimary

Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma

NCT02611037Phase 2CompletedPrimary

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

NCT05795595Phase 1Completed

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

NCT05308966CompletedPrimary

Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)

NCT04400539Phase 2Recruiting

The IMmunotherapy Pleural 5-ALA PDT

NCT06037941Not ApplicableRecruitingPrimary

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

NCT02863055Phase 2TerminatedPrimary

Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

NCT04162015Phase 1Active Not RecruitingPrimary

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

NCT04525859Phase 1CompletedPrimary

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

NCT03917043Phase 1Recruiting

APG-2449 in Patients With Advanced Solid Tumors

NCT06318286Phase 2RecruitingPrimary

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma

NCT02649829Phase 1CompletedPrimary

Autologous Dendritic Cell Vaccination in Mesothelioma

NCT06910449Not ApplicableRecruitingPrimary

Hemithoracic Arc Radiotherapy Post Pleural Decortication

Scroll to load more

Research Network

Activity Timeline